Vifor Pharma acquires Priority Review Voucher
von
, 17.02.2020, 06:00 Uhr
Regulatory News: Vifor Pharma today announced that it has agreed to purchase a US Food and Drug Administration (FDA) priority review voucher (PRV). A PRV entitles the holder to obtain priority review for a New Drug Application or Biologics License Application thereby reducing the target review time and potentially leading to a faster approval. The transaction is subject to customary closing